Drugs are most commonly administered to patients as solid dosage forms given orally. Although this statement is less true in anaesthesia than in many other fields of medicine, a substantial amount of drug therapy prescribed by anaesthetists is given by mouth. It is often assumed that once a drug has been given by mouth it will be well absorbed and achieve its desired therapeutic effects. However, such a drug has to pass many barriers before it reaches the systemic circulation. The problems of poor biovailability of drugs are now well known, particularly in respect of digoxin (Johnson et al., 1973) . We are now more aware of the properties a drug must possess in order to be absorbed and this article concentrates on these and other factors that influence the absorption.
FORMULATION OF DRUG PREPARATIONS
Before a drug can be absorbed after oral administration it has to pass through a number of stages, illustrated in figure 1. First, the tablet must disintegrate in the stomach contents and subsequently it must dissolve in the gastrointestinal contents. These processes may now be largely predicted and a series of in vitro tests is available to ensure that drugs conform to accepted standards. The science of biopharmaceutics exists to study the influence of pharmaceutical formulation on the in vivo performance of a drug. It might be thought, that with these problems, it would be easier to give a drug in solution by mouth. However, further problems mitigate against this, including solubility and stability of the drug in question, taste, and convenience of the preparation used. Thus for most drugs, tablets or capsules are the only practicable formulation.
It is often forgotten that a tablet or capsule contains many ingredients other than active drug. Table  I lists some of the components in a "typical" tablet, with the function of each ingredient. Problems may arise if one of the ingredients is changed, even though the amount of drug in the tablet has not M. ORME, M.A., M.D., F.R.C.P., Department of Pharmacology and Therapeutics, New Medical School, Ashton Street, Liverpool L693BX.
changed. In Australia the formulation of phenytoin was changed because of a shortage of lactose, and calcium sulphate was substituted (Bochner et al., 1972) . This led to a loss of therapeutic effect and a decrease in plasma concentration of phenytoin. Many patients had their phenytoin dosage increased and when lactose was again included in the formulation, the improved absorption resulted in an excessive number of toxic effects. It should not be forgotten, also, that some of the ingredients may be responsible for the adverse effects of drugs. There is increasing concern about the number of tablets that contain tartrazine as a yellow colouring dye. Tartrazine is a potent cause of allergic skin rashes.
Problems over the absorption of drugs from different formulations, all containing the same amount of the drug, have recently come to the front of the political arena and used as an argument in favour of generic prescribing. In the past, there have been problems with the bioavailability of such drugs as tetracycline, digoxin, tolbutamide, phenylbutazone and chloramphenicol. However, most of these problems have now been resolved through stricter application of B.P. standards. It is sometimes possible to show differences in the bioavailability of two formulations of the same drug, using the plasma concent- ration profile as the yardstick of performance. In general, such examples of bioinequivalence have shown only small differences and it is doubtful if there are many of clinical significance.
MECHANISMS OF ABSORPTION
There are four possible mechanisms for the absorption of a drug from solution in the gastrointestinal fluids.
Passive diffusion
This is the most usual mechanism for the absorption of drugs across a membrane such as the lining of the gastrointestinal tract. Passive diffusion is the natural tendency for molecules to move from a region of high concentration to one of low concentration. In order to be absorbed, a drug molecule must be in solution at the surface of the cell membrane, and its lipid solubility must enable it to dissolve in the hydrophobic inner layers of the cell membrane. Finally the molecule passes out into the aqueous phase inside the cell. Drug absorption depends, in this situation, largely on the physicochemical properties of the drug, although the surface area of the gut available for absorption is of considerable importance. The rate of penetration by a drug through the cell membrane is expressed in terms of the permeability constant:
Thus, increased thickness of the membrane is accompanied by a reduction in the rate of absorption. The major source of variation in absorption is the partition coefficient of a drug between lipid membrane and aqueous surroundings. Lipid soluble drugs have high permeability constants and penetrate cell membranes with ease. Water soluble (or hydrophilic) drugs partition poorly into lipids and thus pass through the membrane rather slowly. Thus, for absorption, a drug must possess a balance of water solubility, so that it can dissolve in the aqueous phase at the cell surface, and lipid solubility so that it can penetrate the membrane.
IONIZED AND UNIONIZED DRUGS One of the main factors influencing lipid solubility of a drug, apart from chemical structure, is its state of ionization. Ionized drug is not lipid soluble and only unionized drug can cross cell membranes. Most drugs are weak acids or weak bases and exist in solution as an equilibrium between the ionized and unionized forms. Increased accumulation of the drug occurs on that side of the membrane where pH favours a greater ionization of the drug and this is called the pH partition hypothesis. The pH of gastric fluid varies between 1.5 and 6.0, while the intestinal fluid is considerably more alkaline.
The fraction of a drug unionized at the absorption site is controlled by two factors; the pH of the medium and the pKa of the drug, according to the Henderson-Hasselbalch equation. Thus for acids:
and for bases:
The pKa of a drug is a characteristic of that drug and is defined as the pH at which 50% of the drug is unionized. Figure 2 shows the pKa values of some common acidic and basic drugs. It is possible for a drug to have two (or more) sites of ionization and thus to have two pKa values (amphoteric drugs). The pH partition hypothesis can best be explained by examining an example such as warfarin, an acidic drug with a pKa of 4.8. At a pH of 4.8 it is 50% unionized, but at one pH unit more, from the above equation that ratio has shifted 10 to 1 in favour of the ionized drug (remembering the logarithmic scale for pH). Thus at pH 5.8,91% of the drug is ionized and 9% unionized. Thus absorption of warfarin is favoured in an acidic medium (e.g. the stomach) where the large majority of the drug is in the unionized form. This shows that the fraction unionized only changes dramatically for those acids with pKa values between 2.5 and 7.5 (or bases with pKa values between 5 and 11). Those weak acids with pKa values greater than 7.5 are essentially unionized at all pH values. In practice, the pH partition hypothesis does not explain all aspects of absorption by passive diffusion. Some quaternary ammonium compounds which are always ionized are absorbed, albeit very slowly and erratically. Warfarin is absorbed from the alkaline contents of the small intestine, where it should be largely in the ionized form. There is, of course, an equilibrium between the ionized and unionized states and the discrepancies in warfarin absorption may be explained by the far greater surface area for absorption in the small intestine compared with the stomach.
Active transport
This term implies the utilization of energy to convey a drug across a cell membrane, usually against a concentration gradient. This mechanism is normally highly specific for the substrate carried, for example amino-acids, and is not really of importance for the absorption of drugs. Active transport is involved in the renal excretion of many acids (e.g. penicillin) and bases, but the only drugs of which the absorption may be mediated by active transport are methyldopa, levodopa and 5-fluorouracil.
Filtration through pores
There are known to be pores between cells which may allow the passage of drugs and other molecules. These pores are very small, and the total area of the pores is small compared with the total cell membrane area. Compounds require a molecular weight of less than 100 to traverse these pores and most drugs have molecular weights between 100 and 350. Thus, only compounds such as ethanol and methanol (which are water soluble) are likely to use this route of absorption, and there is considerable doubt over its role in the absorption of drugs.
Pinocytosis
The mechanism of absorption, whereby microscopic particles are engulfed by the cell membrane, is not important in the case of drugs. However, it may be relevant to the uptake of macromolecules.
SITES OF DRUG ABSORPTION

Stomach and small intestine
Most drugs given by mouth are designed to be absorbed from the small intestine (and to a small extent from the stomach). However, drugs are also absorbed from, and designed to be given by, alternative sites in the gastrointestinal tract.
Buccal absorption
Many drugs are well absorbed across the buccal mucosa according to the principles described above. In general, the buccal route is not used extensively for absorption of many drugs because most patients in the Western World dislike keeping a drug preparation in contact with the buccal mucosa for long enough to ensure drug absorption. However, the Chinese use this route extensively and oral contraceptive steroids are often administered in the form of postage stamp size pieces of rice paper, onto which the drugs are absorbed, and which are stuck to the roof of the mouth.
In general, there are two situations which specifically favour this route. First, if the drug in question is destroyed by gastric acidity, then absorption via the buccal route may be feasible. An example of this would be the use of syntocinon in the induction of labour. Second, a drug may be given by the buccal route in order to avoid extensive first-pass metabolism in the gut wall or liver (see below); blood supplying the buccal mucosa is returned directly into the systemic circulation. In addition, the speed of absorption may enable a more rapid onset of clinical effect (e.g. glyceryl trinitrate, buprenorphine (Heel et al., 1979) ).
Rectal absorption
This route may be chosen to avoid direct gastric irritation or because of therapeutic customs in different countries. In addition, it may be used when oral absorption is not possible (for example in the period immediately after operation). The principles governing absorption at this site are the same as those in the upper gastrointestinal tract, but the area for absorption is very small and it is therefore surprising how well drugs are absorbed. Indomethacin is absorbed from the rectum almost as well as from the small intestine (Baber et al., 1980) , and diazepam (Mandelli, Tognoni and Garattini, 1978) and morphine (Westerling et al., 1982) are also well absorbed from the rectum. Metronidazole is commonly given by the rectal route in patients unable to take the drug by mouth. Absorption from the rectum is complete and rapid (Ioannides et al., 1981) and the economics of this route of administration are markedly cheaper than the i.v. route. Contrary to popular belief, most of the drug absorbed from the rectum passes via the hepatic portal vein to the liver and so the first-pass effect is not avoided.
FACTORS AFFECTING DRUG ABSORPTION FROM THE GUT
There are a number of factors which may affect the absorption of drugs from the gut (table IT) . We have already considered the formulation of the drug and the way it may affect drug absorption, and the influence of pH on drug absorption. In addition, six additional factors require consideration:
Gastric emptying time
We have already noted that acidic drugs are absorbed more rapidly from the alkaline small intestine than from the acidic stomach, in spite of being highly unionized in the latter situation. The total absorption area of the small intestine is probably approximately 200 m 2 compared with 1 m 2 for the stomach, and this probably accounts for the greater intestinal absorption. Since the rate of absorption of all compounds (acids or bases) is faster from the small intestine than from the stomach, a controlling factor in the rate of drug absorption is the rate of gastric emptying. If gastric emptying is slowed, then clearly the rate of drug absorption is likely to be reduced. Gastric emptying may be slowed by food in the stomach (especially fat) or by drugs such as propantheline, while metoclopramide will increase the rate of gastric emptying. The effects of anaesthetics on gastric emptying have already been considered (Nimmo, 1984) . It is unlikely that variations in gastric empyting affect the total amount of drug absorbed, but they do affect the rate of drug absorption.
Enteric coated preparations
Since some drugs are destroyed by gastric acid (for example, penicillin) or are irritant to the stomach (for example, aspirin), a material resistant to acid is sometimes used to coat the preparation. Obviously absorption of the drug cannot commence until the preparation reaches the alkaline small intestine. If gastric empyting is delayed, it may be some hours before any drug is absorbed and such a preparation should not be used if a rapid onset of action is required.
Intestinal transit time
Once the drug is in the small intestine, at the normal rates of intestinal transit, some 4-10 h are available for drug absorption. As the intestinal contents move into the colon, the resulting compaction of the solid contents limits further dissolution of the drug. Most drugs are absorbed very rapidly and in studies where drug concentrations have been measured in the hepatic portal vein, peak concentrations often occur by 30-40min (Back et al., 1982a) . Although the absorption of some lipid-insoluble drugs may be impaired if intestinal transit time is increased (for example in diarrhoea), in general it would require a severe degree of diarrhoea to reduce the absorption of most modern drugs.
Gastrointestinal disease
The effect of gastrointestinal disease has only recently been studied in respect of drug absorption. One would expect that drug absorption would be impaired in severe malabsorption states, but the literature is conflicting in this regard. Thus prednisolone absorption has been reported to be reduced in patients with Crohn's disease (Shaffer et al., 1983 ) while other workers have reported no reduction (Milsap et al., 1983) . In coeliac disease, the absorption of drugs may be normal, reduced, or even, paradoxically, increased. This is considered in a later section, while the whole subject of drug absorption in disease is reviewed elsewhere (Parsons, 1977) .
Intestinal blood flow
Blood flow assures continuous absorption by removing drug that passes through the membranes of the gastrointestinal wall. If a highly lipid-soluble drug passes very rapidly across the gut wall, the rate-limiting step in the absorption of that drug may be the rate of intestinal blood flow, and its ability to carry away absorbed drug. In practice, very few drugs are absorbed rapidly enough for blood flow to be a rate limiting factor, but ethanol and methanol are examples of such drugs.
Presence of other substances in the gastrointestinal tract
Drugs. The presence of other drugs or ions may modify the absorption of the drug in question. Thus tetracycline, a known chela ting agent, is poorly absorbed in the presence of ions including calcium, magnesium or iron, since insoluble chelates may be formed. Calcium is present in milk and the doctor who advises a patient to take his tetracycline with a glass of milk (to reduce gastric irritation) should not be surprised at the subsequent therapeutic failure. In the case of iron salts therapeutic failure is even greater, since not only will the tetracycline fail to be absorbed, but the iron salts too (Neuvonen, 1976) . Bentonite, an excipient in, for example, some PAS preparations, is responsible for the marked impairment of absorption of rifampicin when the two drugs are given in combination (Boman, Lundgren and Stjernstrom, 1975) . Cholestyramine, an ion exchange resin, reduces the absorption of acidic drugs, for example warfarin, if the two drugs are given at the same time. In this situation an interval of 2 h should elapse between the two drug administrations, and it is preferable to give warfarin before cholestyramine (Robinson, Benjamin and McCormack, 1971) .
Food. It used to be thought that food in the stomach delays but does not prevent drug absorption, largely by slowing down the rate of gastric emptying. Thus, patients were told to take drugs before food, unless the drugs were irritant to the gastric mucosa. However, recent studies have shown a rather variable effect of food on the rate of drug absorption and this has been the subject of recent review (Melander, 1978) . Table HI lists some of those drugs for which there is information concerning the effect of food on absorption.
PHARMACOKINETIC CHARACTERISTICS OF DRUGS
Drug metabolism by the gut bacteria
It is often assumed that the gut bacteria in man play no part in the absorption of drugs under normal circumstances, but this is not so. The normal microflora in the colon possess a wide range of enzymes that can metabolize drugs. Thus sulphasalazine (Salazopyrin) has its azo bond reduced by gut bacteria in the colon to produce the two component parts, sulphapyridine and 5-amino salicylic acid. While both these metabolites possess therapeutic activity, the parent compound is almost certainly inactive (Schroder and Campbell, 1972) .
Enterohepatic circulation
Drug metabolism by gut bacteria plays its most important role in the enterohepatic recirculation of drugs (illustrated in figure 3 ). During the passage of a drug through the gut wall and then, via the portal vein, through the liver, it may be conjugated directly with glucuronic acid or sulphate. This conjugate is excreted in the bile and passes down the small intestine to the colon. In the colon, the gut bacteria (which possess both glucuronidase and sulphatase enzymes) split the conjugate from the drug molecule, thus liberating the unchanged drug which may then be reabsorbed. Drugs which undergo an enterohepatic circulation include indomethacin (Kwan et al., 1976) and ethinyloestradiol (Orme, Back and Breckenridge, 1983) .
It is uncertain how important the enterohepatic circulation is as a source of absorbed drug, and it is inherently difficult to quantitate. In theory at least, oral use of broad spectrum antibiotics, by killing the gut bacteria, may destroy the enterohepatic circulation, leading to reduced plasma concentrations of the drug and a loss of therapeutic effect. How important this is in man is questionable; although the effect can be demonstrated in animal models (Back et al., 1980b) , no clinical interaction can be demonstrated between broad spectrum antibiotics such as ampicillin, and ethinyloestradiol (Back et al., 1982b) (fig. 4) .
Drug metabolism in the gut wall
There is no doubt that many drugs are metabolized to some extent by the gut wall. A wide variety of hydrolytic, reductive, oxidative and conjugating enzymes are present in the cells of the gut wall and are available to metabolize drugs. Metabolism of drugs in the gut wall is part of the "first-pass metabolism" or presystemic alimination that needs further explanation at this stage.
First-pass metabolism. Once a drug molecule has been absorbed into the gut wall, it has to pass through the remainder of the gut wall, and thence via the hepatic portal vein through the liver before it reaches the systemic circulation. Once in the sys-tcmic circulation it is available to exert therapeutic effects. In the process of absorption, all the drug has to pass this route, but once absorbed into the systemic circulation, much smaller amounts of drug go to the gut wall and liver-in proportion to the blood flow to these organs. This initial passage of all the drug through the liver and gut wall exposes the drug to metabolism in these sites ("first-pass" metabolism) and in this way the amount of drug reaching the systemic circulation is reduced. Lignocaine (Boyes et al., 1971 ) is one of many drugs undergoing firstpass metabolism (table IV) .
Bioavailability of drugs. There is often confusion over the terms bioavailability and absorption, and the two terms are not synonymous. A drug that is 100% bioavailable will of course be completely absorbed, but the reverse is not the case. Once the drug has passed into the gastrointetinal mucosa it is absorbed into the body, but it only becomes bioavailable after passing the liver. Absolute bioavailability is best measured by comparing the plasma concentration v. time profile of a drug (area under the plasma concentration v. time curve or AUC) after both i.v. and oral doses: Bioavailability = AUg after oral dosing AUC after i.v. dosmg Figure 4 shows two examples of this method of calculating bioavailability. On the left are shown the curves for norethisterone and it can be seen that the two lines are almost identical, indicating almost complete bioavailability. On the right are shown the curves for ethinyloestradiol and it can be seen that the AUC for the oral dose is much smaller than that for the i.v. dose. This may be the result either of poor absorption by the gut or of first-pass metabolism. We can show that the drug is well absorbed by giving a radiolabelled dose of the drug by mouth and counting the radioactivity in the urine and faeces over a period of time. Almost total recovery of radioactivity in the urine indicates complete absorp- tion. The recovery of significant amounts of radioactivity in the faeces does not necessarily indicate poor absorption because further studies may reveal that this radioactivity comes from metabolites which have been excreted in the bile. Relative bioavailability is a term used when comparing the bioavailability of two different formulations of the same drug, but it provides no information on absolute bioavailability.
First-pass metabolism in the gut wall. It is now realized that first-pass metabolism may take place either in the gut wall or in the liver. Initial studies tended to concentrate more on the liver; propranolol and lignocaine are extensively metabolized in the liver on first pass. It is more difficult to quantify gut wall metabolism. In vitro studies with samples of intestinal mucosa may indicate that the gut wall is capable of metabolizing the drug, but to quantitate the contribution of the gut wall to the first pass effect necessitates catheterization of the hepatic portal vein (usually placed for other purposes). Blood samples may be taken from the hepatic portal vein during absorption of a drug and by measuring both unchanged drug and metabolite, the contribution of the gut wall to first-pass metabolism may be quantitated (Back et al., 1982a) . Table IV lists some of the drugs with low bioavailability from extensive firstpass metabolism. In some instances (e.g. lignocaine (Stenson, Constantine and Harrison, 1971) ) the extent of first-pass metabolism is so great that the drug is ineffective by mouth. In other instances, the oral dose of the drug (e.g. morphine (Brunk and Delle 1974) , isoprenaline (Conolly et al., 1972) , chlormethiazole (Pentikainen et al., 1978) is much larger than the usual i.v. dose to produce a therapeutic effect.
The range of metabolic processes in the gut wall is probably fairly limited and conjugation reactions are those most commonly encountered (either with glucuronic acid or sulphate). In some situations, if two drugs are given together that are both conjugated in the gut wall, they may compete for the conjugating enzymes. The end result is likely to be enhanced bioavailabily of both drugs; thus salicylamide increases the bioavailability of isoprenaline (George, Blackwell and Davies, 1974) and ascorbic acid increases the bioavailability of ethinyloestradiol (Back et al., 1981) , in both instances by competition for available sulphate.
Active metabolites and "prodrugs"
Metabolism in the gut wall results usually in the inactivation of the drug; but metabolism in the liver may produce a metabolite that has therapeutic activity. Table V lists some of those drugs possessing metabolites with therapeutic activity. In some instances the drug acts primarily through metabolites and the parent drug has little or no intrinsic activity. Thus, ethynodiol and norethynodrel are both converted quantitatively to norethisterone. This has produced the concept of prodrugs-a drug is given deliberately as a compound-inactive in its own right, but metabolized to the active drug when the compound has been absorbed. This may be done to avoid local gastrointetinal effects; thus esters of aspirin may be given which are converted in the gut wall and the liver to aspirin and salicylic acid-thus minimi7ing gastric irritation. Similarly, talampicillin (or Pivampicillin), an ester of ampicillin, is hydrolysed after absorption to produce ampicillin, the active antibiotic, and this may reduce the diarrhoea that sometimes occurs with ampicillin. A prodrug may be synthesized to protect the compound from first-pass metabolism, although this has not yet been used much commercially. Propranolol is much better absorbed into the systemic circulation as propranolol hemisuccinate than as propranolol itself because of the protection of the succinate (Garceau, Davis and Hasegawa, 1978) . 
